NCT06466382Recruiting
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 21 May 2024
- Start date
- 31 Mar 2025
- Primary completion date
- Jun 2027
- Lead sponsor
- Swiss GO Trial Group
- Diseases
- Ovarian cancer
- NCT number
- NCT06466382
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 31 Mar 2025 to the primary completion date, Jun 2027
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another clinical trial on the same indication
Other illness
- Any other malignancy within the last 5 years which has an impact on the prognosis of the patient
- Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance
Other
- ECOG ≥3
- Pregnant or lactating women
Who the study is looking for
- Age ≥ 18 years
- Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
- No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
- Envisaged surgical candidate for interval debulking after 2 cycles of treatment
- Patients have adequate hematology, liver and kidney functions
- Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
- ECOG 0-2
- Written informed consent according to national legal and regulatory requirements prior to any project specific procedures
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kantonsspital Aarau AG Coordinator of this site? Confirm its status | Aarau | Switzerland | Not yet recruiting |
| Kantonsspital Baden AG Coordinator of this site? Confirm its status | Baden | Switzerland | Recruiting |
| Universitätsspital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
| Inselspital Bern (University Hospital for Medical Oncology) Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| Thurgau AG Frauenfeld / Münsterlingen Coordinator of this site? Confirm its status | Frauenfeld | Switzerland | Recruiting |
| HFR Fribourg - Hôpital cantonal Coordinator of this site? Confirm its status | Fribourg | Switzerland | Recruiting |
| Hirslanden Klinik St. Anna Coordinator of this site? Confirm its status | Lucerne | Switzerland | Recruiting |
| HOCH Health Ostschweiz - Kantonsspital St. Gallen Coordinator of this site? Confirm its status | Sankt Gallen | Switzerland | Recruiting |
| Kantonsspital Winterthur Coordinator of this site? Confirm its status | Winterthur | Switzerland | Recruiting |
| University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.